Jermasek Douglas 4

What Happened

• Douglas Jermasek, EVP of Corporate Strategy at Unicycive Therapeutics (UNCY), received a grant of 169,500 restricted stock units (RSUs) reported as an award on May 14, 2026. The Form 4 lists the acquisition price as $0.00 because this is a compensation award (derivative security), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-05-14 (reported on Form 4 filed 2026-05-20).
• Security and amount: 169,500 restricted stock units (derivative award) at $0.00 per share.
• Vesting: RSUs vest 1/3 on each anniversary of the grant for 3 years, subject to continued service (per footnote).
• Shares owned after transaction: Not stated on the filing.
• Timeliness: Form 4 filed 6 days after the grant (appears to be a late filing).

Context

• RSUs convert to common stock only as they vest; there was no immediate cash payment or open‑market trade reported. Such awards are common executive compensation and do not, by themselves, indicate a buy or sell decision by the insider. The late filing is an administrative compliance issue worth noting for monitoring insider reporting practices.